BioStock: Lipum’s CEO reflects on the year and comments on Eurostars funding
2024 was an eventful year for Lipum, setting the stage for an equally exciting 2025. The year kicks off with the final report from the clinical phase I trial of the drug candidate SOL-116, followed by preparations for a phase II trial to demonstrate treatment efficacy in patients with rheumatoid arthritis. Additionally, Lipum recently secured funding from Eurostars for a project with Age Labs, focused on predicting which patients are most likely to respond to the treatment.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se